Company Overview and News

 
Airbus and Atos awarded major cyber security contract to protect key EU institutions

2018-10-08 globenewswire
Munich, Paris, 8 October 2018 - Airbus Defence and Space, through its Airbus CyberSecurity unit and partnering with Atos as coprime entity, have been selected by the Council of the European Union to provide cyber security expertise, products, services and solutions to help protect the IT systems of 17 European institutions, services and agencies.
ATONV

 
Airbus et Atos remportent un important contrat de cybersécurité pour la protection des institutions européennes

2018-10-08 globenewswire
Munich, Paris, 8 Octobre 2018 - Airbus Defence and Space a été sélectionné, par l'intermédiaire de son entité Airbus CyberSecurity et en partenariat avec Atos comme second maître d'oeuvre, par le Conseil de l'Union européenne pour la fourniture d'expertise, de produits, de services et de solutions de cybersécurité destinés à protéger les systèmes informatiques de 17 institutions, services et agences européennes.
ATONV

 
ECA2018-172 - Information Regarding the Merger of Syntel, Inc. (SYNT)

2018-10-02 nasdaqtrader
At a special meeting held on October 1, 2018, the shareholders of Syntel, Inc. (SYNT) approved a merger with Atos SE. The anticipated closing date is expected to be Tuesday, October 9, 2018. The details are as follows:
ATONV

 
ATOS: Les actionnaires de Syntel votent en faveur de l'acquisition par Atos

2018-10-02 globenewswire
Paris, le 2 octobre 2018 - Atos SE (EURONEXT: ATO), leader international de la transformation digitale, a annoncé aujourd'hui que les actionnaires de Syntel avaient approuvé l'acquisition de Syntel par Atos lors de l'assemblée extraordinaire du 1er octobre 2018.
ATONV

 
ATOS : Syntel shareholders vote in favor of acquisition by Atos

2018-10-02 globenewswire
Paris, October 2, 2018 - Atos SE (EURONEXT:ATO), a global leader in digital transformation, today announced that Syntel's shareholders approved Syntel's acquisition by Atos at the special meeting held in connection with the transaction on October 1st, 2018.
ATONV

 
Merger Arbitrage Mondays - September 17, 2018

2018-09-17 seekingalpha
Committee on Foreign Investment in the United States (CFIUS) review of Atos SE's proposed acquisition of Syntel (SYNT) has been completed.
SYNT ATONV

 
Atos ranked N°1 by the Dow Jones Sustainability Indices (DJSI World and Europe) in the digital sector for its corporate responsibility and sustainability performance

2018-09-17 globenewswire
Paris, 17 September 2018 - Atos, a global leader in digital transformation, today announces that it has been ranked n°1 as the most sustainable company in its industry group in the Dow Jones Sustainability Index (DJSI) World and Europe, following the publication of the 2018 DJSI results.
ATONV

 
Atos classé numéro 1 de la responsabilité d'entreprise et du développement durable dans le numérique par le Dow Jones Sustainability Index (DJSI World & Europe)

2018-09-17 globenewswire
Paris, 17 septembre 2018 - Atos, leader international de la transformation digitale, est classé numéro 1 du secteur des services numériques et logiciels dans les indices de développement durable du DJSI Monde et Europe à l'occasion de la publication des résultats 2018 du DJSI.
ATONV

 
Atos signs strategic partnership with Technical University of Denmark to deliver its latest Atos Quantum Learning Machine

2018-09-13 globenewswire
Paris, Copenhagen, September 13, 2018 - Atos, a global leader in digital transformation, today announces a new strategic partnership with the Technical University of Denmark (DTU) on quantum computing and learning.
ATONV

 
Atos signe un partenariat stratégique avec l'Université Technique du Danemark pour l'équiper du nouveau modèle de l'Atos Quantum Learning Machine

2018-09-13 globenewswire
Paris, Copenhague, 13 septembre 2018 - Atos, leader international de la transformation digitale, annonce aujourd'hui la signature d'un nouveau partenariat stratégique avec l'Université Technique du Danemark (DTU) pour développer l'apprentissage et l'informatique quantique.
ATONV

 
Atos - IT Space Winner; Global Play

2018-08-24 seekingalpha
Editor's note: Seeking Alpha is proud to welcome PCS Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
ATONV

 
Atos reconnu leader des services IoT par NelsonHall

2018-08-24 globenewswire
Paris, 24 août, 2018 - Atos, leader international de la transformation digitale, est positionné 'Leader'* des services IoT (Internet des Objets) dans le dernier rapport de NelsonHall [1].
CCHGY CCH ATONV

 
Atos named a Leader in IoT Services by global analyst firm NelsonHall

2018-08-24 globenewswire
Paris, August 24, 2018 - Atos, a global leader in digital transformation, today announces that it has been named a 'Leader'* by global research and advisory firm NelsonHall in its latest NEAT analysis on Internet of Things (IoT) Services.
CCHGY CCH ATONV

 
Statement from Atos

2018-08-08 globenewswire
Bezons, August 8, 2018. Atos, a global leader in digital transformation, today would like to react to the note issued by the sell-side analyst from Credit Suisse which has downgraded its recommendation on Atos' stock.
ATONV

 
Atos accompagne la transformation digitale du leader américain de l'assurance CNA Financial Corporation

2018-07-30 globenewswire
Atos fournira un modèle de services innovant pour accélérer l'adoption du Cloud et conduire la transformation digitale en mode agile
CNA ATONV

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...